国际权威医学期刊《内科学年鉴》正式刊发了LivaNova公司针对阻塞性睡眠呼吸暂停开展的Osprey临床研究的12个月随访数据。该研究旨在评估治疗方案对患者长期疗效与安全性的影响，此次公布的结果为医疗界提供了重要临床证据。
作为专注于创新医疗技术的全球性企业，LivaNova通过这项前瞻性研究进一步夯实了其在睡眠呼吸疾病治疗领域的技术积累。最新数据将有助于推动相关疗法的标准化应用，为临床医生制定个体化治疗方案提供参考依据。
（注：Osprey研究聚焦于阻塞性睡眠呼吸暂停这一常见睡眠障碍疾病，其长期随访结果对改善患者生活质量和降低并发症风险具有重要意义）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.